Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human IL-7 Protein, 20µg  

ActiveMax® Recombinant Human IL-7 Protein, 20µg

ActiveMax® Recombinant Human IL-7 Protein, Asp 26 - His 177, produced in human 293 cells (HEK293), Tag free

Synonym: Recombinant Human Protein, IL7,Interleukin-7

 

More details

IL7-H4219-20

Availability: within 7 days

238,00 €

Background
Interleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis. IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL-7 binds to the IL-7 receptor, a heterodimer consisting of Interleukin-7 receptor alpha and common gamma chain receptor. Il-7 promotes hematological malignacies (acute lymphoblastic leukemia, T cell lymphoma). Elevated levels of IL-7 have also been detected in the plasma of HIV-infected patients. IL-7 as an immunotherapy agent has been examined in many pre-clinical animal studies and more recently in human clinical trials for various malignancies and during HIV infection. IL-7 could also be beneficial in improving immune recovery after allogenic stem cell transplant.

Source
ActiveMax® Recombinant Human IL-7 Protein (ActiveMax® Human IL-7) Asp 26 - His 177 (Accession # AAH47698) was produced in human 293 cells (HEK293)

Molecular Characterization
ActiveMax® Human IL-7 contains no "tag", and has a calculated MW of 17 kDa. The predicted N-terminus is Asp 26. DTT-reduced Protein migrates as 24 kDa and 26 kDa in SDS-PAGE due to different glycosylation.

Endotoxin
Less than 1.0 EU per μg of the ActiveMax® Human IL-7 by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC). 

Bioactivity
Measured by its binding ability in a functional ELISA. Immobilized Human IL-7, Tag Free (Catalog # IL7-H4219) at 10μg/mL (100 μL/well) can bind Human IL-7 R alpha, Fc Tag (Catalog # ILA-H5258) with a linear range of 0.078-1.25 μg/mL.

 References

(1) Heufler C, et al. 1993, J. Exp. Med. 178 (3): 1109–14.
(2) Kröncke R, et al. 1996, Eur. J. Immunol. 26 (10): 2541–4.
(3) Sawa Y, et al. 2009, Immunity 30 (3): 447–57.
(4) Muegge K, et al. 1993, Science 261 (5117): 93–5.
(5) Noguchi M, et al. 1994, Science 262 (5141): 1877–80.
(6) Snyder KM,et al. 2006, Leuk. Lymphoma 47 (7): 1222–8.

The following products could also be interesting for you: